Get the latest tech news
By knocking out a protein duo’s “bodyguard” role, researchers have exposed a hidden weakness in pancreatic cancer | It’s a discovery that could lead to smarter, more effective treatments for one of the deadliest cancers.
By knocking out a protein duo’s “bodyguard” role, researchers have exposed a hidden weakness in pancreatic cancer. It’s a discovery that could lead to smarter, more effective treatments for one of the deadliest cancers.
Now, though, a new study led by researchers from Indiana University’s (IU) School of Medicine has identified a way to weaken PDAC’s built-in defenses, offering a more effective treatment strategy for it and, potentially, other aggressive cancers. “This research shows us a brand new vulnerability in pancreatic cancer,” said Melissa Fishel, PhD, study co-author and tumor cell biologist at the IU School of Medicine. Unexpectedly, the study showed that CAFs rely on redox proteins like PRDX1 and Ref-1, meaning that the tumor and its stroma are in a chemical partnership, keeping each other alive in the harsh environment of pancreatic cancer.
Or read this on r/tech
